Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
Lyra Medical develops a safe way to implant an organ-support mechanism in women suffering from pelvic organ prolapse. The company's Self-Retaining Support technology is used in the flagship Lyra system for anterior vaginal wall, apex, and uterine prolapse. The support platform may also be applicable in other pelvic organ disorder conditions, including rectocele and urinary incontinence, as well as other clinical areas such as hernias.
Lyra Medical has a robust IP portfolio, including approved US and EU patents and pending applications in other regions. Lyra has completed two clinical studies, with a total of 70 patients, showing excellent results. The company is obtaining EU and Israeli regulatory approval (CE mark and AMAR) with a product launch in Israel and strategic EU markets to follow. Lyra has signed an international distribution agreement with an EU-based strategic partner.